Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Ovid Therapeutics Inc. (OVID) USD0.001

Sell:$4.01 Buy:$4.03 Change: $0.02 (0.50%)
NASDAQ:1.00%
Market closed |  Prices as at close on 6 December 2019 | Switch to live prices |
Sell:$4.01
Buy:$4.03
Change: $0.02 (0.50%)
Market closed |  Prices as at close on 6 December 2019 | Switch to live prices |
Sell:$4.01
Buy:$4.03
Change: $0.02 (0.50%)
Market closed |  Prices as at close on 6 December 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Ovid Therapeutics Inc. (Ovid) is a biopharmaceutical company. The Company is engaged in developing medicines for patients and families living with rare neurological disorders. Its lead drug candidate is OV101. The Company’s second lead drug candidate is OV935. OV101 (gaboxadol) is a delta-selective GABAA receptor agonist. Ovid is developing OV101 for use in both Angelman syndrome and Fragile X syndrome to potentially restore tonic inhibition and relieve several of the symptoms of these disorders. Ovid has initiated the Phase II STARS trial of OV101 in adults with Angelman syndrome and a Phase I trial in adolescents with Angelman syndrome or Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies.

Contact details

Address:
1460 Broadway Ste 15044
NEW YORK
10036-7329
United States
Telephone:
+1 (646) 6617661
Website:
www.ovidrx.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
OVID
ISIN:
US6904691010
Market cap:
$191.74 million
Shares in issue:
47.82 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Jeremy Levin
    Chairman of the Board, Chief Executive Officer
  • Thomas Perone
    Senior Vice President, General Counsel and Corporate Secretary
  • Dirk Haasner
    Senior Vice President - Global Regulatory Affairs
  • Timothy Daly
    Vice President - Finance, Corporate Controller
  • Amit Rakhit
    Chief Medical and Portfolio Management Officer
  • Jason Tardio
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.